Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US4330001060
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00Q53VYM7
HIMS
Hims & Hers Health Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Household & Personal Products · THEMEFOLIO: $HLTH
NAME
Hims & Hers Health Inc
ISIN
US4330001060
TICKER
HIMS
MIC
XNYS
REUTERS
HIMS.N
BLOOMBERG
HIMS US
Wed, 05.08.2026       Hims & Hers Health
US4330001060

Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigati...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Hims & Hers Health
US4330001060

New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses,...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Hims & Hers Health
US4330001060

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financi...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Hims & Hers Health
US4330001060

LOS ANGELES, July 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (" Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The inv...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Hims & Hers Health
US4330001060

New York, New York--(Newsfile Corp. - July 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses,...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Hims & Hers Health
US4330001060

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“ Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Hims & Hers Health
US4330001060

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Hims & Hers Health
US4330001060

Law Offices of Howard G. Smith announces an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABO...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Hims & Hers Health
US4330001060

The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PU...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS) responded to the lawsuit filed today by the Federal Trade Commission (FTC): This lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims....
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 17.07.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will co...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.07.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Hims brand. As the company reimagines how everyone can access proactive, comprehensive care that helps them feel great, Dr. Vinjamoori will provide the clinical guidance that shape...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper’s comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Her...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligib...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its formal entry into Japan. This milestone puts the full weight of Hims & Hers’ technology, data, and clinical infrastructure behind a platform that supports weight managem...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest consumer health platform and marking its official entry into Australia. This milestone puts the full weight of Hims & Hers’ technology, data, and clinical infrastruct...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France,...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Healt...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised tr...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 21.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continui...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Secur...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant t...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates thr...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Hims & Hers Health
US4330001060

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims &...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customer...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Hims & Hers Health
US4330001060

NEW YORK and NEW ORLEANS, March 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS)....
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.03.2026       Hims & Hers Health
US4330001060

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims &...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.03.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medi...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       Hims & Hers Health
US4330001060

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS &...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.02.2026       Hims & Hers Health
US4330001060

Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HO...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Hims & Hers Health
US4330001060

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On February 7, 2026, The New York Times reporte...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare ex...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business c...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.02.2026       Hims & Hers Health
US4330001060

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements an...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.02.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions desig...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Hims & Hers Health
US4330001060

Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims &am...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.01.2026       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it’s heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “Rich People Live Longer” with a simple message: the era of health as a lux...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Hims & Hers Health
US4330001060

Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care. This press release features multimedia. View the full...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent completion of Hims & Hers’ acquisition of Livewell, a trusted Canadian digital health platform offering access to a variety of treatments, with a focus on weight loss. Build...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent acquisition of Livewell, a trusted Canadian digital health platform focused on weight loss. Through this expansion, Hims & Hers is well-positioned to usher in the next era o...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio’s advanced blood sampling devices, the acquisition will help accelerate efforts...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of outstanding Class A common stock over the next three years. This new program follows the successful completion of the...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company’s first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Hims & Hers Health
US4330001060

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. Labs measures key markers over time and provides doctor-developed action plans that can power real shifts in health outcome...
Read more
Hims & Hers Health
Technical Analysis Termsheets Terminal
Permalink